Celltrion Settlement Provides US Date For Aflibercept Entry

Resolution Comes Just Days After FDA Approval For Eylea Biosimilar

 
• By Dave Wallace
  
Celltrion can launch its Eydenzelt aflibercept biosimilar from Dec. 31, 2026 (Shutterstock)

More from Deals

More from Business